C Robert Horsburgh
Overview
Explore the profile of C Robert Horsburgh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
1725
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Phillips P, Peloquin C, Sterling T, Kaur P, Diacon A, Gotuzzo E, et al.
Am J Respir Crit Care Med
. 2025 Mar;
PMID: 40080768
Background: Evaluation of optimal dosing has generally been inadequate during TB drug development. Fluoroquinolones are central to TB treatment. We aimed to determine the dose of levofloxacin needed to achieve...
2.
Kaur P, Chaisson L, Kiragu Z, Buddadhumaruk P, Austin A, Gao Y, et al.
Contemp Clin Trials
. 2025 Mar;
152:107875.
PMID: 40064371
Background: Current guidelines for the treatment of multidrug-resistant/rifampin-resistant tuberculosis (MDR/RR-TB) are based on clinical trials evaluating fixed duration regimens. However, when a regimen succeeds, it remains unknown whether a shorter...
3.
Tzelios C, Malatesta S, Carney T, White L, Weber S, Thomson S, et al.
Clin Infect Dis
. 2025 Feb;
PMID: 39973802
Background: Adverse drug reactions (ADRs) to tuberculosis (TB) medications make treatment completion challenging. We investigated the impact of alcohol, human immunodeficiency virus (HIV), and other patient determinants on ADRs and...
4.
Menzies N, Marks S, Hsieh Y, Swartwood N, Beeler Asay G, Skarbinski J, et al.
Am J Respir Crit Care Med
. 2025 Feb;
PMID: 39928299
Rationale: Individuals surviving TB disease may experience chronic sequelae that reduce survival and quality-of-life. These post-TB sequalae are not generally considered in estimates of the health impact of TB disease....
5.
Chen C, Xue H, Horsburgh C, Amour M, Hatherill M, Tameris M, et al.
Chest
. 2025 Feb;
PMID: 39909102
Background: There is an ongoing debate about whether clearance of Mycobacterium tuberculosis infection occurs and at what magnitude. Recent studies quantifying "uncertainty zones" of interferon-gamma release assays (IGRAs) provide a...
6.
Burman W, Luczynski P, Horsburgh C, Phillips P, Johnston J
Lancet Infect Dis
. 2024 Nov;
25(2):e86-e98.
PMID: 39612926
We did a systematic review and meta-analysis of trials of treatment for rifampicin-susceptible tuberculosis to evaluate the representativeness of participants compared with characteristics of the global population of people with...
7.
Rosen L, Thielking A, Dugdale C, Montepiedra G, Kalk E, Kim S, et al.
Clin Infect Dis
. 2024 Nov;
PMID: 39544107
Background: Although prior studies of tuberculosis-preventive treatment (TPT) for pregnant people with human immunodeficiency virus (PPWH) report conflicting adverse pregnancy outcome (APO) risks, international guidelines recommend TPT for PPWH. Methods:...
8.
Burman W, Horsburgh C, Johnston J
Lancet Infect Dis
. 2024 Oct;
24(12):e727.
PMID: 39481423
No abstract available.
9.
von Reyn C, Arbeit R, Horsburgh C
N Engl J Med
. 2024 Oct;
391(17):1662-1663.
PMID: 39476355
No abstract available.
10.
Campbell J, Lavache D, Garing A, Sabharwal V, Haberer J, Dubois M, et al.
Open Forum Infect Dis
. 2024 Sep;
11(9):ofae494.
PMID: 39238842
In the United States, tuberculosis (TB) screening is recommended for pregnant individuals with TB risk factors. We conducted a retrospective study of perinatal TB infection testing and treatment in a...